Vandria Awarded €3.8M in Prestigious Innosuisse and Eurostars Grants to Advance Innovative Drug Programs for Age-Related Diseases of the CNS and Muscle Vandria is advancing a portfolio of mitophagy inducers to address age-related chronic diseases of the CNS, muscle, lung and liverInnosuisse grant totalling CHF 2.5M (€2.7M) to support early clinical...

Vandria Announces $20.6M (CHF18M) Series A Financing Led by ND Capital to Drive CNS Clinical Program and Mitochondrial Therapeutics Platform Vandria emerges from stealth announcing its $20.6M (CHF18M) Series A financing led by ND CapitalLead candidate VNA-318 is a clinic-ready, brain-penetrant, mitophagy inducer shown to improve memory and...